Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year

  • Selecta Biosciences Inc SELB and Swedish Orphan Biovitrum AB BIOVF announced topline results from the Phase 3 DISSOLVE I & II trials of SEL-212 in adult patients with chronic refractory gout. 
  • Also Read: Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts.
  • The DISSOLVE I (the U.S. Study) met its primary endpoint, with 56% of patients receiving monthly doses of SEL-212 at 0.15 mg/kg achieving a response (defined as achievement and maintenance of reduction in serum urate (SU) <6mg/dL for at least 80% of the time during month six). 
  • The DISSOLVE II (the Global Study) also met its primary endpoint, with 47% receiving monthly doses of SEL-212 at 0.15 mg/kg, achieving a response. 
  • SEL-212 combines Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase).
  • In patients 50 years and older, the response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II.
  • 75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals.
  • Favorable safety profile with 3.4% of patients with infusion reactions at high dose.
  • Regulatory submission in the U.S. is anticipated in the first half of 2024.
  • Price Action: SELB shares are down 5.56% at $1.21 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!